Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) have earned a consensus recommendation of “Reduce” from the eleven research firms that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $23.5667.
A number of research firms have recently commented on FMS. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, May 6th. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a report on Tuesday, July 28th. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research report on Friday, May 8th. Finally, Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th.
Get Our Latest Research Report on Fresenius Medical Care AG & Co. KGaA
Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA Stock Performance
Shares of FMS stock opened at $23.07 on Monday. The firm’s 50 day moving average is $23.94 and its 200 day moving average is $23.12. The stock has a market capitalization of $12.39 billion, a P/E ratio of 11.95, a PEG ratio of 4.29 and a beta of 0.77. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The business had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. On average, sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.
In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.
Featured Articles
- Five stocks we like better than Fresenius Medical Care AG & Co. KGaA
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
